Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post Transplant Cyclophosphamide for GVHD Prophylaxis in Renal Insufficiency
NCT02360111Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Patients with Grade II-IV Chronic Graft Versus Host Disease at 2 years. Started Feb 2015; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02360111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360111.